Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803263 | 0.86 | NOS3 (0.38) | ALDH1A1CA1CA12CA2CA9 | |
| SCHEMBL7942433 | 0.85 | KDM4E (0.36) | DPP4PREPFAPCHRNB2CHRNB4 | |
| SCHEMBL27057436 | 0.83 | KDM4C (0.42) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL23806119 | 0.83 | KDM4C (0.42) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL10127581 | 0.80 | CA1 (0.41) | ALDH1A1CA1CA12CA2CA9 | |
| SCHEMBL23975219 | 0.80 | TDP1 (0.37) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23056505 | 0.79 | NAMPT (0.35) | ALDH1A1CA1NAMPTKDM4CCHRNB2 | |
| SCHEMBL24810541 | 0.79 | TET2 (0.40) | KDM4CKDM4AKDM2A | |
| SCHEMBL12573374 | 0.79 | DPP4 (0.38) | DPP4 | |
| SCHEMBL15830431 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009147221-A1 | SMALL MOLECULE LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| EP-3684763-B1 | PYRIMIDIN-4-CARBAMATE OR UREA DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| WO-2019034688-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| US-9927430-B2 | Pro-substrates for live cell applications | PROMEGA CORPORATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-9927430-B2 | Pro-substrates for live cell applications | PROMEGA CORPORATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-20170007614-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-01-12 | — | — | US | disclosed |
| US-20150307475-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| WO-2015116806-A1 | PRO-SUBSTRATES FOR LIVE CELL APPLICATIONS | PROMEGA CORPORATION (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150212078-A1 | PRO-SUBSTRATES FOR LIVE CELL APPLICATIONS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2015-07-30 | — | — | US | disclosed |
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| US-20140171404-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171403-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2009147221-A1 | SMALL MOLECULE LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307475-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | ALDH1A1 3712/4885CA1 2346/4885NAMPT 1688/4885 |
| US-20150212078-A1 | PRO-SUBSTRATES FOR LIVE CELL APPLICATIONS | PREP, SI, GLB1 | ALDH1A1 3263/4885CA1 2987/4885NAMPT 1455/4885 |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | ALDH1A1 4110/4885CA1 4819/4885NAMPT 2661/4885 |
| US-20140171403-A1 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | ALDH1A1 4843/4885CA1 3524/4885NAMPT 790/4885 |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | ALDH1A1 2821/4885CA1 2883/4885NAMPT 2681/4885 |
| US-20140171404-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | ALDH1A1 4601/4885CA1 3013/4885NAMPT 1086/4885 |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | GPR119, GPR27, GCGR | ALDH1A1 1827/4885CA1 4370/4885NAMPT 2427/4885 |
| US-20170007614-A1 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | ALDH1A1 4843/4885CA1 3524/4885NAMPT 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.